TSS
ARQT icon

Two Sigma Securities’s Arcutis Biotherapeutics ARQT Stock Holding History

Two Sigma Securities’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Buy
+12,639
New +$294K 0.03% 801
2024
Q4 		– Sell
-14,938
Closed -$139K – 1699
2024
Q3 		$139K Buy
+14,938
New +$147K ﹤0.01% 2228

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Securities's ARQT Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 12,639 shares worth $331K. The stake represents 0.03% of the portfolio and ranks #801 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in ARQT as recently as Q3 2024.

Two Sigma Securities first reported a position in ARQT in Q3 2024 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Two Sigma Securities held 12,639 shares of Arcutis Biotherapeutics worth $331K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Two Sigma Securities position in Q2 2026.
  • Arcutis Biotherapeutics made up 0.03% of Two Sigma Securities's portfolio in Q2 2026, its #801 holding.
  • Two Sigma Securities first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.